Slide 1: Suven Life Sciences Q3 FY19 Result Update
Suven Life Sciences Q3 FY19 Result Update Demerger to improve margins 7th February 2019 CMP: Rs. 220 Quarterly Highlights: Target Rs 280 Revenue stood at Rs 129 Cr vs 163 Cr, de growth of 21% Recommendation BUY YoY. EBITDA stood at 36 Cr vs 51 Cr, de growth of 31% YoY. Stock Info Margins stood
Slide 2: Valuations and Financial Snapshot
Sector -Pharma Valuations: Management is hopeful of receiving a positive response for SUVN 502 which will be key trigger for the company. Demerger of the CRAMS and Drug discovery business will be positive for the Company, as it will reduce the R&D expense and in turn will improve margins. Management
Slide 3: Quarterly Update
Sector -Pharma Quarterly Update: Particulars in Crore Q3FY19 Q2FY19 Q3FY18 QoQ YoY Sales 129 90 163 44% -21% Other operating income 1 Total Revenue 129 90 164 44% -21% Other Income 5.8 6.6 3.3 -13% 75% Total Income 135 96 167 40% -19% Expenses Cost Of Material 62 41 51 52% 22% Employee Benefit 15 14
Slide 4: Income Statement and Balance Sheet
Sector -Pharma Income Statement: Income Statement Rs in Crore FY18 FY19E FY20E Revenue 625 590 699 Cost of materials 175 233 245 Gross Margins 72% 60% 65% Operation and other expenses 217 136 189 Total Operating Expenses 392 369 433 EBIDTA 233 221 266 EBIDTA Margin 37% 37% 38% Depreciation 21 27 29
Slide 5: Cash Flow and Key Ratios
Sector -Pharma Cash Flow: Cash Flow Rs Crore FY18 FY19E FY20E Profit Before taxes 230 213 257 Add:- Depreciation 25 27 29 Change in Working Capital -92 26 21 Cash generated from operations 148 270 311 Taxes paid 44 70 85 Net cash flow from operating activities 105 200 226 Purchase of fixed assets -4
Slide 6: Arihant Research Desk Contact and Disclaimer
Sector -Pharma Arihant Research Desk Email: research@arihantcapital.com Tel. : 022-42254800 Head Office Registered Office #1011, Solitaire Corporate park , Arihant House Building No. 10, 1st Floor, E-5 Ratlam Kothi Andheri Ghatkopar Link Road Indore - 452003, (M.P.) Chakala, Andheri (E). Tel: (91-73